Annovation Biopharma, a startup that is developing next-generation anesthesia products, has raised $8 million from a consortium of investors that includes Boston venture capital firm Atlas Venture, according to a Boston Business Journal report.
Other investors include the Partners Innovation Fund, affiliated with hospital system Partners HealthCare, and N.J.-based drug maker The Medicines Company. The funding may be expanded to $11 million and is expected to carry the startup through pre-clinical development to clinical proof of concept of Annovation's lead product.
The product is based on technology from Douglas Raine, MD, and his laboratory in the department of anesthesia, critical care, and pain medicine at Massachusetts General Hospital in Boston.
Related Articles on Anesthesia:
Clinical Trial Shows Drug Exparel Reduces Pain, Adverse Opioid Side Effects
Donald Bell Named First CRNA to Chair Tennessee Board of Nursing
Sheridan Healthcare Names Dr. Andrew Greenfield Senior VP of Anesthesiology
Other investors include the Partners Innovation Fund, affiliated with hospital system Partners HealthCare, and N.J.-based drug maker The Medicines Company. The funding may be expanded to $11 million and is expected to carry the startup through pre-clinical development to clinical proof of concept of Annovation's lead product.
The product is based on technology from Douglas Raine, MD, and his laboratory in the department of anesthesia, critical care, and pain medicine at Massachusetts General Hospital in Boston.
Related Articles on Anesthesia:
Clinical Trial Shows Drug Exparel Reduces Pain, Adverse Opioid Side Effects
Donald Bell Named First CRNA to Chair Tennessee Board of Nursing
Sheridan Healthcare Names Dr. Andrew Greenfield Senior VP of Anesthesiology